 |
|
|
| |
Sofosbuvir Plus Peg-IFN/RBV for 12 Weeks vs Sofosbuvir/RBV for 16 or 24 Weeks in Genotype 3 HCV-Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study
|
| |
| |
from Jules: 91% SVR in GT3 naives with cirrhosis & 86% SVR in GT3 treat-exp with cirrhosis....100% SVR Gt2 Sof/Rbv 24 weeks
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Graham R. Foster1, Stephen Pianko2, Curtis Cooper3, Ashley Brown4, Daniel Forton5, Ronald G. Nahass6, Jacob George7, Eleanor Barnes8, Diana M. Brainard9, Benedetta Massetto9, Ming Lin9, Bin Han9, John G. McHutchison9, G. Mani Subramanian9, Kosh Agarwal10
1Queen Mary's University of London, Barts Health, London, United Kingdom; 2Monash Health and Monash University, Melbourne, Australia; 3The Ottawa Hospital, University of Ottawa, Ottawa, Canada; 4Imperial College Healthcare National Health Service Trust, London, United Kingdom; 5St George's University of London, London, United Kingdom; 6ID Care, Hillsborough, New Jersey, USA; 7Storr Liver Centre, Westmead Millennium Institute, University of Sydney, and Westmead Hospital, Sydney, New South Wales, Australia; 8Nuffield Department of Medicine, Oxford NHIR BRC and representing STOP-HCV, London, United Kingdom; 9Gilead Sciences, Inc., Foster City, California, USA; 10Institute of Liver Studies, King's College Hospital, London, United Kingdom
|
| |
|
|
|
|
|
